- Bangladesh outspin Afghanistan to level ODI series
- Monaco claim comeback win to retake second spot in Ligue 1
- 'Way too far': Amsterdam in shock after 'frightening' violence
- Bonzi fells Norrie in Metz for first ATP title
- Biden, Trump to meet at White House ahead of historic return
- Jorgensen the hero as Australia edge England in Twickenham thriller
- Vinicius treble as Real Madrid crush Osasuna, Villarreal rise
- A 'jungle': Rome's teeming jail lays bare Italy's prison ills
- Asalanka knock seals four-wicket Sri Lanka win over New Zealand
- Australia beat England 42-37 in Twickenham thriller
- Wolves end wait for Premier League win, Man City aim to snap losing streak
- Gaza mediator Qatar bows out, source says, in sign of impasse
- Musiala stars as Bayern go six clear, Dortmund lose again
- 'Racing career: completed it!' announces cycling great Cavendish
- Waring holds one-shot Abu Dhabi lead as McIlroy struggles
- Vinicius treble helps Real Madrid crush Osasuna
- Iran urges Trump to change 'maximum pressure' policy
- Goal-shy Lecce fire coach Gotti
- Comeback king 'Cav' set a benchmark doing the thing he loved
- UK's Queen Camilla to miss events as Kate returns to public life
- Cycling great Cavendish announces retirement
- Rome's Trevi Fountain unveils tourist catwalk during cleaning
- Defence puts a smile on All Blacks faces ahead of French Test
- Kagiyama wins NHK Trophy despite early slip
- Afghan women not barred from speaking to each other: morality ministry
- China's Xi hails 'new chapter' in relations with Indonesia
- Injured Darry out of All Blacks tour with Cane in doubt
- Pakistani separatists kill 26 in railway station blast
- China's Xi meets Indonesian president in Beijing
- Key nominees for the 2025 Grammy Awards
- Top art collector displays rare treasures in Madrid
- Pakistani separatists kill 25 in railway station blast
- South Sudan floods affect 1.4 million, displace 379,000: UN
- Japan's Sasaki set to follow Ohtani with move to MLB
- Konstas hits unbeaten 73 in audition to open for Australia
- Pakistani separatists kill 22 in railway station blast
- No culprit found five years on from Notre Dame fire
- Reeking mud sparks health fears in Spain flood epicentre
- Bogusz goal edges LAFC past Whitecaps in MLS playoffs
- N. Korea jams GPS signals, affecting ships, aircraft in South
- Indonesia volcano catapults vast ash tower into sky
- Cavs ride huge first half to crushing win over Warriors
- Over 130 homes lost in California wildfire as winds drop
- New tools give researchers hope for fungus-ravaged US bats
- Germany marks 1989 Berlin Wall fall with 'Preserve Freedom' party
- Heat, air pollution, disease: How climate change affects health
- Boeing to face civil trial over 2019 MAX crash
- Over 130 homes lost in California wildfire as winds abate for now
- 'No excuses', says Farrell after All Blacks end Irish home win streak
- Furious de Zerbi talks of leaving after Marseille lose to Auxerre
Nobel winner's ingenious chemistry could lead to cancer breakthroughs
"All kinds of crazy things" is how Carolyn Bertozzi, a 2022 Nobel laureate, describes her life's work. Actually performing "chemistry in cells and in people."
When she started her research in 1997, the Stanford professor was aiming only to observe the evolution of certain molecules on the surface of cancer cells.
Today, thanks to her discoveries, at least two companies -- including one she co-founded -- are developing innovative cancer treatments.
The multitude of applications made possible by her findings are impressive: delivering treatments with extreme precision, understanding better how drugs act inside the body, visualizing certain bacteria, to name a few.
"I can't even really enumerate them. The vast majority of those applications I would never have foreseen," she told AFP in an interview.
The Nobel Prize committee recognized Bertozzi's pioneering advances on Wednesday, making her only the eighth woman to win the chemistry prize, at just 55 years old.
- Lego pieces -
Her journey began when she found she had a passion for organic chemistry, while taking pre-medicine courses at Harvard.
The subject is notoriously -- many say fiendishly -- difficult, but she credits an "amazing professor," the late David Evans, for bringing it to life -- and changing the course of her life.
"I said, forget the med school thing. I'm going to be a chemist," said Bertozzi, whose sister is a professor of applied mathematics, and father a retired professor of physics.
After completing her post-doctorate and joining the faculty at UC Berkeley, she wanted to take a closer look at glycans: complex carbohydrates, or sugars, located on the surface of cells, which "go through structural changes" when they become cancerous.
At the time, "there was no tool to image sugars, like in a microscope, for example," she said.
She had an idea that would require two chemical substances that fit together perfectly, like pieces of lego.
The first lego is fed to cells via a sugar. The cell metabolizes it and places it on the tip of the glycan. The second piece of lego, a fluorescent molecule, is injected into the body.
The two lego pieces click together, and voila: hidden glycans reveal themselves under a microscope.
This technique is inspired by "click chemistry" developed independently by Denmark's Morten Meldal and American Barry Sharpless -- Bertozzi's co-winners. But their discoveries relied on using copper as a catalyst, which is toxic to the body.
One of Bertozzi's great leaps was achieving the same type of ultra-efficient reaction without copper.
The other tour de force: making it all happen without wreaking havoc with other processes in the body.
"The beauty of it is that you can take the two Legos and click them together, even if they're surrounded by millions of other very similar plastic toys," she explained.
She coined the term "bioorthogonal chemistry," meaning a reaction that doesn't interfere with other biochemical processes. Perfecting the technique took 10 years.
- 'Cycle of science' -
Researchers are now leveraging these breakthroughs to develop cancer treatments.
Glycans on cancer cells "are able to hide the cancer cell from the immune system -- and so your body can't fight it, it can't see it," she explains.
Using bioorthogonal chemistry, "we made a new type of medicine, which basically acts like a lawnmower," says Bertozzi.
The first lego attaches to the cancer cell's surface, and the second, which clips onto it, is equipped with an enzyme that "mows off the sugars as if they're just grass, it cuts the grass and the sugars fall off," she says with a smile.
The drug is currently being tested in the early stages of a clinical trial.
Another company is seeking to use bioorthogonal chemistry to better target cancer treatment. The first lego piece is injected into a tumor, then a second, which carries the drug, attaches itself and acts only on its target.
"So that allows the oncologist to treat the tumor and kill the tumor without exposing the person's entire body to a toxic chemical," she says.
"What the future holds is hopefully an impact in human health," says Bertozzi. "But the people who decide that more so than myself, are the students and postdocs that join my lab."
Hundreds of them, current and former, filled her email box with messages of congratulations this morning.
"That really is the cycle of science -- it's being mentored and then mentoring" she adds. And "mentoring students gives you an opportunity to amplify the impact of your science."
T.Ward--AMWN